Targeted Agent Rova-T Active in Small-Cell Lung Cancer
This video discusses the phase I trial of rovalpituzumab (Rova-T) for the treatment of patients with small-cell lung cancer.
Currently, topotecan is the only US Food and Drug Administration (FDA)-approved agent for the treatment of relapsed small-cell lung cancer (SCLC).
In this video, Gregory P. Kalemkerian, MD, of the University of Michigan Health System, discusses a phase I trial of rovalpituzumab (Rova-T), a novel agent that targets DLL3 that has shown activity in the second-line treatment of patients with SCLC.
Kalemkerian gave a presentation on SCLC at the 2017 Multidisciplinary Thoracic Cancers Symposium, held March 16–18 in San Francisco.
Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs
Read about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.
